Date Title Description PDF
10 May 2023 On P&L The Company releases the press release related to the first quarter 2023 financial results Download
10 May 2023 On P&L The Company releases the first quarter 2023 financial results presentation Download
25 Apr 2023 On business and financial situation ROVI commences clinical development of a new three-monthly formulation of Letrozole (Letrozole LEBE) Download
21 Feb 2023 On business and financial situation The Company releases the full year 2022 financial results presentation. Download
21 Feb 2023 On business and financial situation The Company releases the press release related to the full year 2022 financial results. Download

Pages

Date Title Description PDF
23 Feb 2022 Annual Report regarding remuneration of the members of the Board of Directors ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors Download
23 Feb 2022 Annual Corporate Governance Report ROVI releases the 2021 Annual Corporate Governance Report Download
21 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 Download
15 Feb 2022 On business and financial situation ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. Download
14 Feb 2022 Share buy-back , stabilisation and treasury stock programme Share Buyback Program: transactions conducted between 7 February 2022 and 11 February 2022 Download

Pages

Date Title Description PDF
09 Jun 2015 Convocatorias y Acuerdos de Juntas y Asambleas Generales Download
03 Jun 2015 Acuerdos estratégicos con terceros Download
06 May 2015 Convocatorias y Acuerdos de Juntas y Asambleas Generales Download
29 Apr 2015 Información sobre resultados (2) Download
29 Apr 2015 Información sobre resultados Download

Pages